Advertisement
BCRX or BLUE or BPMC
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 1 FA rating(s) are green whileBLUE’s FA Score has 1 green FA rating(s), and BPMC’s FA Score reflects 0 green FA rating(s).
- BCRX’s FA Score: 1 green, 4 red.
- BLUE’s FA Score: 1 green, 4 red.
- BPMC’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 3 TA indicator(s) are bullish while BLUE’s TA Score has 6 bullish TA indicator(s), and BPMC’s TA Score reflects 5 bullish TA indicator(s).
- BCRX’s TA Score: 3 bullish, 5 bearish.
- BLUE’s TA Score: 6 bullish, 4 bearish.
- BPMC’s TA Score: 5 bullish, 4 bearish.
Price Growth
BCRX (@Biotechnology) experienced а -3.89% price change this week, while BLUE (@Biotechnology) price change was 0.00% , and BPMC (@Biotechnology) price fluctuated -0.12% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.88%. For the same industry, the average monthly price growth was +14.10%, and the average quarterly price growth was +6.14%.
Reported Earning Dates
BCRX is expected to report earnings on Jul 31, 2025.
BLUE is expected to report earnings on May 14, 2025.
BPMC is expected to report earnings on Jul 30, 2025.
Industries' Descriptions
@Biotechnology (+4.88% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BCRX | BLUE | BPMC | |
| Capitalization | 2.22B | 48.7M | 8.26B |
| EBITDA | 47.6M | -215.81M | -66.42M |
| Gain YTD | 41.090 | -40.408 | 46.698 |
| P/E Ratio | N/A | N/A | N/A |
| Revenue | 503M | 53.1M | 562M |
| Total Cash | 295M | 70.7M | 576M |
| Total Debt | 795M | 368M | 467M |
BCRX | BLUE | BPMC | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 30 | 77 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 20 Undervalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 69 | 100 | 51 | |
SMR RATING 1..100 | 100 | 98 | 94 | |
PRICE GROWTH RATING 1..100 | 37 | 46 | 37 | |
P/E GROWTH RATING 1..100 | 100 | 100 | 65 | |
SEASONALITY SCORE 1..100 | 50 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BLUE's Valuation (20) in the Biotechnology industry is in the same range as BCRX (32) and is somewhat better than the same rating for BPMC (82). This means that BLUE's stock grew similarly to BCRX’s and somewhat faster than BPMC’s over the last 12 months.
BPMC's Profit vs Risk Rating (51) in the Biotechnology industry is in the same range as BCRX (69) and is somewhat better than the same rating for BLUE (100). This means that BPMC's stock grew similarly to BCRX’s and somewhat faster than BLUE’s over the last 12 months.
BPMC's SMR Rating (94) in the Biotechnology industry is in the same range as BLUE (98) and is in the same range as BCRX (100). This means that BPMC's stock grew similarly to BLUE’s and similarly to BCRX’s over the last 12 months.
BPMC's Price Growth Rating (37) in the Biotechnology industry is in the same range as BCRX (37) and is in the same range as BLUE (46). This means that BPMC's stock grew similarly to BCRX’s and similarly to BLUE’s over the last 12 months.
BPMC's P/E Growth Rating (65) in the Biotechnology industry is somewhat better than the same rating for BCRX (100) and is somewhat better than the same rating for BLUE (100). This means that BPMC's stock grew somewhat faster than BCRX’s and somewhat faster than BLUE’s over the last 12 months.
| BCRX | BLUE | BPMC | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 13 days ago 76% | 2 days ago 81% |
| Stochastic ODDS (%) | 2 days ago 85% | 13 days ago 90% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 84% | 13 days ago 77% | 2 days ago 77% |
| MACD ODDS (%) | 2 days ago 83% | 13 days ago 90% | 2 days ago 76% |
| TrendWeek ODDS (%) | 2 days ago 80% | 13 days ago 88% | 2 days ago 74% |
| TrendMonth ODDS (%) | 2 days ago 82% | 13 days ago 79% | 2 days ago 70% |
| Advances ODDS (%) | 3 days ago 79% | 29 days ago 77% | 27 days ago 73% |
| Declines ODDS (%) | 7 days ago 80% | 14 days ago 88% | 6 days ago 73% |
| BollingerBands ODDS (%) | 2 days ago 87% | 13 days ago 90% | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 87% | 13 days ago 85% | 2 days ago 63% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JUCY | 22.27 | 0.01 | +0.05% |
| Aptus Enhanced Yield ETF | |||
| GSID | 63.83 | -0.11 | -0.17% |
| Goldman Sachs MarketBeta Intl Eq ETF | |||
| RFFC | 58.64 | -0.20 | -0.34% |
| ALPS Active Equity Opportunity ETF | |||
| VONE | 273.25 | -0.95 | -0.35% |
| Vanguard Russell 1000 ETF | |||
| TMFE | 27.75 | -0.12 | -0.43% |
| Motley Fool Capital Efficiency 100 ETF | |||
BCRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To BCRX | 1D Price Change % | ||
|---|---|---|---|---|
| BCRX | 100% | -3.63% | ||
| VCYT - BCRX | 46% Loosely correlated | +0.18% | ||
| CRNX - BCRX | 40% Loosely correlated | -2.27% | ||
| INSM - BCRX | 39% Loosely correlated | +7.75% | ||
| COGT - BCRX | 39% Loosely correlated | -2.16% | ||
| VKTX - BCRX | 39% Loosely correlated | -0.65% | ||
More | ||||
BPMC and
Correlation & Price change
A.I.dvisor indicates that over the last year, BPMC has been loosely correlated with VERA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BPMC jumps, then VERA could also see price increases.
| Ticker / NAME | Correlation To BPMC | 1D Price Change % | ||
|---|---|---|---|---|
| BPMC | 100% | -0.02% | ||
| VERA - BPMC | 47% Loosely correlated | -2.30% | ||
| LYRA - BPMC | 44% Loosely correlated | -12.90% | ||
| ORIC - BPMC | 42% Loosely correlated | -3.69% | ||
| ROIV - BPMC | 42% Loosely correlated | -0.79% | ||
| ARQT - BPMC | 42% Loosely correlated | -1.15% | ||
More | ||||